FDA grants argenx's efgartigimod Fast Track designation for treatment of primary Sjogren's disease, presents positive Phase 2 results evaluating VYVGART in Sjogren's disease at EULAR 2025 ($575.46, 0.00)
HHS, CMS issue press release on specific targets for Trump's MFN
Halozyme CEO very confident in 'clinical benefit' of subcutaenous formulated drugs, insulation from IRA price negotiations ($50.23, 0.00)
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Summary - US Pre-market trading update
StreetAccount Sector Summary - Healthcare Pre-Market
argenx upgraded to outperform from neutral at Baird ($560.90, 0.00)
StreetAccount Sector Summary - Healthcare Weekly Recap
Biopharma stocks pressured again on MFN drug pricing worries
Powered by FactSet Research Systems Inc.